Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Thyroid Neoplasms 1Neoplasm Metastasis 1

Interventions

Cisplatin 47pembrolizumab 37Magnetic Resonance Spectroscopy 33Specimen Handling 27Radiotherapy, Intensity-Modulated 21Cetuximab 19Nivolumab 18Carboplatin 16Platinum 151,2-diaminocyclohexaneplatinum II citrate 15Radiotherapy 14Biopsy 12Paclitaxel 11Gemcitabine 10Docetaxel 10Surveys and Questionnaires 9Radiation 9Immunoglobulin G 7Disulfides 7toripalimab 6cemiplimab 6Ipilimumab 6Fluorouracil 6Bevacizumab 6dostarlimab 5atezolizumab 5Watchful Waiting 5Taxes 5Immune Checkpoint Inhibitors 5Drug Therapy 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyrotropin Alfa × Head & Neck × 30 days × Clear all
NCT03841617 2026-06-03

The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
30 enrolled
Head & Neck

Neoplasm Metastasis, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡